Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3U54CA260543-02S2
Grant search
Key facts
Disease
COVID-19Start & end year
20202025Known Financial Commitments (USD)
$136,800Funder
National Institutes of Health (NIH)Principal Investigator
PROFESSOR Aravinda DeSilvaResearch Location
United States of AmericaLead Research Institution
UNIV OF NORTH CAROLINA CHAPEL HILLResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Abstract High-quality recombinant antigens and reliable and accurate SARS-CoV-2 serological assays are urgently needed for surveillance and for defining the immune mechanisms of viral pathogenesis, viral clearance, and protection against reinfection. Core B of the UNC SARS-CoV-2 Serological Sciences Center of Excellence will apply state-of-the-art strategies to establish methods for the production of milligram quantities of homogeneous recombinant spike protein CoV antigens with versatile tags and site-specific labels and use these antigens to develop sensitive and reliable singleplex and multiplex Ab detection assays. Core B will interact and support all the projects driven by the center and collaborators' by providing recombinant antigens and serological assays to characterize the serum antibody response, elucidate Fc effector functional profiles, and isolate and sequence antigen-specific immunoglobulin gene repertoire.